Volume 14, Issue 3 , Pages 282-289, March 2008
Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched Related Donor
Article Outline
Abstract
The lower morbidity and mortality of reduced-intensity conditioning (RIC) regimens have allowed allogeneic hematopoietic cell transplantation (HCT) in older patients. Unrelated umbilical cord blood (UCB) has been investigated as an alternative stem cell source to suitably HLA matched related (MRD) and adult volunteer unrelated donors. We hypothesized that RIC HCT using UCB would be safe and efficacious in older patients, and compared the treatment-related mortality (TRM) and overall survival (OS) of RIC HCT in patients older than 55 years using either MRD (n = 47) or, in patients with no 5 of 6 or 6 of 6 HLA compatible related donors, UCB (n = 43). RIC regimen consisted of total-body irradiation (TBI; 200 cGy) and either cyclophosphamide and fludarabine (n = 69), or busulfan and fludarabine (n = 16) or busulfan and cladribine (n = 5). The median age of MRD and UCB cohorts was 58 (range, 55-70) and 59 (range, 55-69) years, respectively. acute myelogenous leukemia/myelodysplastic syndrome (AML/MDS) (50%) was the most common diagnosis. All MRD grafts were 6 of 6 HLA matched to the recipient. Among patients undergoing UCB HCT, 88% received 2 UCB units to optimize cell dose and 93% received 1-2 HLA mismatched grafts. The median follow-up for survivors was 27 (range: 12-61) months. The 3-year probabilities of progression-free survival (PFS; 30% versus 34%, P = .98) and OS (43% versus 34%, P = .57) were similar for recipients of MRD and UCB. The cumulative incidence of grade II-IV acute graft-versus-host (aGVHD) disease (42% versus 49%, P = .20) and TRM at 180-days (23% versus 28%, P = .36) were comparable. However, UCB recipients had a lower incidence of chronic graft-versus-host disease (cGVHD) at 1 year (40% versus 17%, P = .02). On multivariate analysis, graft type had no impact on TRM or survival, and the HCT comorbidity index score was the only factor independently predictive for these endpoints. Our study supports the use of HLA mismatched UCB as an alternative graft source for older patients who need a transplant but do not have an MRD. The use of RIC and UCB extends the availability of transplant therapy to older patients previously excluded on the basis of age and lack of a suitable MRD. A careful review of existing comorbidities is necessary when considering older patients for HCT.
Key Words: Allogeneic stem cell transplantation, Umbilical cord blood transplantation, Nonmyeloablative conditioning regimen, Reduced-intensity conditioning regimen
Introduction
Allogeneic hematopoietic cell transplantation (HCT) is an effective therapy for a variety of malignant and nonmalignant hematologic disorders. The high rates of treatment-related morbidity and mortality (TRM) observed with traditional myeloablative conditioning regimens have typically restricted the use of allogeneic HCT to young and relatively healthy patients. Many adult hematologic malignancies manifest clinically in the sixth or seventh decade of life, and because of advanced age and high-risk for TRM, these patients are usually excluded from most conventional myeloablative allogeneic HCT protocols. The advent of reduced-intensity conditioning (RIC) regimens that primarily rely on the graft-versus-tumor effect has allowed allogeneic HCT as a treatment option for these older patients. This approach has been shown to be feasible, lead to long-term engraftment, exhibit a graft-versus-malignancy effect, and result in acceptable TRM 1, 2, 3.
Although a human leukocyte antigen (HLA) matched related donor (MRD) is the preferred donor source, it is available for less than 30% of patients requiring allogeneic HCT 4, 5. Transplantation from adult volunteer unrelated donors also remains limited by the availability of fully HLA matched grafts, and increased HLA disparity in this setting adversely affects overall survival (OS) and increases the risk of graft-versus-host disease (GVHD) 5, 6. Unrelated umbilical cord blood (UCB) has been investigated as an alternative source for hematopoietic stem cells. We have previously reported that UCB HCT using an RIC regimen produces high rates of engraftment with tolerable toxicity 7, 8, 9.
We hypothesized that for older patients without a MRD, UCB could lead to comparable survival and TRM, thus extending the availability of HCT as a therapeutic option for patients who would otherwise be ineligible for transplantation because of lack of a suitable donor. We therefore conducted a study comparing the safety and efficacy of allogeneic HCT after RIC regimen in patients older than 55 years using either MRD or UCB in patients with no MRD.
Methods
Patient Characteristics
Eligibility criteria for HCT using RIC at our institution include older age (≥55 years for MRD and ≥45 years for UCB), presence of significant comorbidity, and history of previous autologous transplant or extensive therapy. Data were collected prospectively on 90 consecutive patients between 55-70 years of age who received RIC HCT between January 2000 and December 2005 using either MRD (n = 47) or, in patients with no 5 of 6 or 6 of 6 HLA compatible related donors, UCB (n = 43). The primary indication for using RIC instead of a conventional myeloablative preparative regimen for all patients was age ≥55 years. Patients were considered for UCB HCT if they had no HLA-compatible related donors (5 of 6 or 6 of 6 HLA-A, B, or DRB1 matches).
Pretransplantation comorbidities were scored retrospectively for all patients using the HCT-specific comorbidity index (HCT CI) described by Sorror et al [10]. The comorbidities captured by this tool include cardiac disorders, cerebrovascular disease, diabetes, altered hepatic function, infection, inflammatory bowel disease, obesity, peptic ulcer disease, psychiatric disturbance, pulmonary abnormalities, renal insufficiency, and rheumatologic disorders. Scores are assigned to various comorbidities based on their severity and a final composite score is then calculated and patients can be assigned to 1 of 3 risk groups: low risk (score 0), intermediate risk (score 1-2), and high risk (score ≥3).
Patients were classified as having standard- or high-risk disease. Standard-risk disease included acute leukemia in first complete remission (CR), chronic myelogenous leukemia (CML) in the first chronic phase, myelodysplastic syndrome (MDS)—refractory anemia, and nonmalignant hematologic disorders; all other diagnoses were categorized as high-risk disease.
Treatment Plan
The majority of patients (n = 69) underwent conditioning with a regimen that included cyclophosphamide (50 mg/kg intravenously on day –6), fludarabine (40 mg/m2 intravenously daily from days –6 through –2), and 200 cGy total-body irradiation (TBI; on day –1). Prior to September 2001, patients received a regimen (n = 16) using busulfan (2 mg/kg orally every 12 hours for 4 doses on days –8 and –7) with the same doses of fludarabine and TBI, or a regimen (n = 5) using the same dose of busulfan and TBI with cladribine (10 mg/m2 intravenously daily from days –6 through –2). Equine antithymocyte globulin (ATG) 15 mg/kg intravenously every 12 hours for 6 doses from days –3 to –1 was added to a subgroup of patients who had not received chemotherapy within 3 months of HCT or a previous autologous transplant (n = 23). All patients received GVHD prophylaxis with cyclosporine (days –3 to at least +100) and mycophenolate mofetil (MMF; days –3 to at least +30). Granulocyte colony-stimulating factor (G-CSF) 5 μg/kg/day intravenously was administered to all patients until the absolute neutrophil count (ANC) was more than 2.5 × 109/L for 2 days. The treatment protocols were approved by the University of Minnesota institutional review board, and all patients gave informed consent prior to transplantation.
MRD and UCB Grafts
All related donor grafts were 6 of 6 HLA matched to the recipient and the target cell dose was at least 3 × 108 NC/kg. Forty-four patients undergoing MRD HCT received G-CSF mobilized peripheral blood stem cell (PBSC) grafts, and 1 patient received a bone marrow graft. In addition, because of inadequate donor mobilization, 2 patients received grafts derived from both PBSC and bone marrow.
Our UCB selection criteria for adults have been previously published 7, 8, 11. UCB grafts were matched at least 4 of 6 HLA-A, -B (antigen level), and -DRB1 (allele level) to the recipient, and in patients receiving 2 UCB units, to each other. Thirty-eight (88%) patients undergoing UCB HCT received grafts consisting of 2 UCB units to optimize cell dose and 40 (93%) received at least 1-2 HLA mismatched units. The median total cryopreserved nucleated cell dose was 3.7 × 107 NC/kg (range: 1.6-7.8 × 107 NC/kg) and CD34+ dose was 4.2 × 105 cells/kg (range: 1.3-16.6 × 105 cells/kg). UCB units were thawed using the method described by Rubinstein et al [12].
Donor Chimerism Analysis
Donor chimerism was determined serially on marrow and/or blood samples on days +21-28, +60, +100, 6 months, and annually after HCT. Chimerism analysis was performed using quantitative PCR of informative polymorphic variable-number tandem repeat (VNTR) or short tandem repeat (STR) regions in recipient and donor 13, 14, and has been described previously [7].
Study Definitions and Statistical Analysis
The primary endpoint was probability of progression-free survival (PFS). Other study endpoints included probability of overall survival (OS) and cumulative incidences of sustained donor engraftment, acute and chronic GVHD (aGVHD, cGVHD), and TRM. PFS was defined as survival in CR or stable partial remission (PR); recurrence after achieving a CR or an increase in existing or new disease sites following a stable PR was considered disease progression. CR was defined as complete absence of disease on clinical, radiologic, and if indicated, pathologic evaluation. PR was defined as ≥50% reduction in sites of known disease. Failure to achieve a PR was defined as persistent disease. Sustained donor engraftment was defined as neutrophil recovery with donor hematopoiesis by day 42 after transplant. Time of neutrophil engraftment was defined as first of 3 consecutive days with an ANC >0.5 × 109/L. Complete donor chimerism was defined as marrow reconstitution of donor origin of at least 90%. Ten patients (UCB = 5, MRD = 5) were censored from engraftment analysis because of death prior to day 21 and before the status of donor chimerism could be ascertained. Standard clinical criteria were used to diagnose and grade GVHD 15, 16. TRM was defined as death within 180 days following HCT without disease progression or relapse.
Comparison of patient and transplant characteristics was performed using chi-square, Fisher's exact, or Wilcoxon's rank sum test as appropriate. Cumulative incidence of engraftment, TRM, and GVHD was calculated by treating deaths from other causes as competing risks [17]. The Kaplan-Meier method was used to plot survival curves for PFS and OS [18]. Both univariate and multivariate Cox regressions were performed with TRM, PFS, and OS as the outcomes [19]. Variables were included in the multivariate model if they were conceptually important, or if they approached or obtained statistical significance in the univariate regression. All multivariate models included donor type (UCB versus MRD) and were adjusted for age at transplant, sex, time from diagnosis to transplant, history of previous transplant, disease risk, recipient-donor HLA disparity, recipient-donor cytomegalovirus (CMV) serologic status, conditioning regimen, use of ATG, aGVHD, cGVHD, and HCT CI score. Acute GVHD (aGVHD) was treated as a time-dependent variable. Event times were measured from date of transplantation to date of death or last contact. All P-values were 2 sided. Analyses were performed in SAS 8.2 and SAS 9.1 (Cary, North Carolina). The analysis was based on follow-up through June 2007.
Results
Patient Characteristics
Patient, disease, and transplant characteristics are summarized in Table 1. The median age at transplant for the entire cohort was 59 years (range: 55-70 years). A significantly higher proportion of patients undergoing UCB HCT received ATG with their conditioning. All UCB grafts were CMV seronegative. UCB units also had a significantly lower cryopreserved cell dose and CD34+ cell dose.
Table 1. Patient, Disease, and Transplant Characteristics
| Characteristics | MRD (n = 47) | UCB (n = 43) | P-value |
|---|---|---|---|
| Median age, years (range) | 58 (55-70) | 59 (55-69) | .22 |
| Gender, male | 33 (70%) | 32 (74%) | .66 |
| Median weight, kilograms (range) | 78 (55-120) | 79 (50-130) | .96 |
| Race | .88 | ||
 White | 43 (91%) | 38 (88%) | |
| Other | 4 (9%) | 5 (12%) | |
| Diagnosis | .07 | ||
| Acute myelogenous leukemia | 10 (21%) | 19 (44%) | |
| Acute lymphoblastic leukemia | 2 (4%) | 2 (5%) | |
| Chronic myelogenous leukemia | 2 (4%) | 1 (2%) | |
| Chronic lymphocytic leukemia | 3 (7%) | 2 (5%) | |
| Myelodysplastic syndrome | 6 (13%) | 10 (23%) | |
| Non-Hodgkin lymphoma | 14 (30%) | 7 (16%) | |
| Hodgkin lymphoma | 2 (4%) | 0 | |
| Multiple myeloma | 6 (13%) | 0 | |
| Other∗ | 2 (4%) | 2 (5%) | |
| Disease risk† | .33 | ||
| Standard | 9 (19%) | 12 (28%) | |
| High | 38 (81%) | 31 (72%) | |
| Prior HCT‡ | 9 (19%) | 3 (7%) | .09 |
| Median time from diagnosis to HCT, months (range) | 25 (3-154) | 13 (3-250) | .24 |
| HCT-specific comorbidity index score§ | .10 | ||
| 0 | 7 (16%) | 15 (36%) | |
| 1-2 | 19 (43%) | 13 (31%) | |
| ≥3 | 18 (41%) | 14 (33%) | |
| Conditioning regimen | .13 | ||
| Cy/Flu/TBI | 33 (70%) | 36 (84%) | |
| Other¶ | 14 (30%) | 7 (16%) | |
| ATG used in conditioning | 6 (13%) | 17 (40%) | <.01 |
| HLA compatibility⊥ | <.01 | ||
| 6 of 6 antigen match | 47 (100%) | 3 (7%) | |
| 5 of 6 antigen match | 0 | 13 (30%) | |
| 4 of 6 antigen match | 0 | 27 (63%) | |
| Recipient-donor CMV serologic status | .02 | ||
| Recipient negative-donor negative | 16 (34%) | 18 (42%) | |
| Recipient negative-donor positive | 8 (17%) | 0 | |
| Recipient positive | 23 (49%) | 25 (58%) | |
| Median cell dose, ×108 NC/kg (range) | 9.2 (3.0-21.2) | 0.4 (0.2-0.8) | <.01 |
| Median CD34+ cell dose, ×106 cells/kg (range) | 5.3 (1.2-15.5) | 0.4 (0.1-1.7) | <.01 |
| Median follow up, months (range) | 37 (18-61) | 24 (12-44) | .33 |
∗Includes 1 patient each with renal cell carcinoma and myelofibrosis in MRD group and renal cell carcinoma and aplastic anemia in UCB group. |
†Standard-risk disease—acute leukemia in first complete remission, chronic myelogenous leukemia in first chronic phase, myelodysplastic syndrome refractory anemia, nonmalignant hematologic disorder; high-risk disease—all other disease categories. |
‡All had prior autologous HCT except for 1 patient in MRD group who had received an MRD myeloablative allogeneic HCT for MDS 8 years prior. |
§Excludes 4 patients (MRD = 3, UCB = 1) for whom sufficient data was not available to calculate the HCT-specific comorbidity score. |
¶Includes busulfan/fludarabine/TBI (n = 16) and busulfan/cladribine/TBI (n = 5). |
⊥Worst HLA match for patients undergoing UCB transplantation using 2 UCB units. |
Sixty-eight (76%) patients had at least 1 comorbid condition; however, the distribution of HCT CI scores among the 2 groups was comparable. The common pretransplant comorbidities observed in our cohort were pulmonary disorders (DLCO and/or FEV1 ≤80%, dyspnea, or requiring oxygen; n = 47), hepatic abnormalities (chronic hepatitis, liver cirrhosis or bilirubin, serum transaminase levels more than the upper limit of normal; n = 17), cardiac abnormalities (coronary artery disease, congestive heart failure, myocardial infarction, or LVEF ≤50%; n = 16), history of prior malignancy (n = 11), psychiatric disturbances (depression or anxiety needing treatment; n = 10), diabetes needing treatment (n = 6), obesity (body mass index >35 kg/m2; n = 6), and infections (n = 5).
Survival
The median follow-up of survivors was 27 months (range: 12-61 months). The probabilities of 3-year PFS and OS were comparable between the 2 groups (Table 2). The probability of PFS at 3 years was 30% (95% confidence intervals [CI], 16%-44%) for recipients of MRD and 34% (95% [CI], 19%-48%) for UCB recipients (P = .98). The probability of OS at 3 years was 43% (95% CI, 29%-58%) for MRD and 34% (95% CI, 17%-50%) for UCB recipients (P = .57) (Figure 1).
Table 2. Study Outcomes
| Endpoint | All patients (n = 90) | MRD (n = 47) | UCB (n = 43) | P-value∗ |
|---|---|---|---|---|
| 3-Year PFS (95% CI) | 32% (22-43) | 30% (16-44) | 34% (19-48) | .98 |
| 3-year OS (95% CI) | 39% (28-50) | 43% (29-58) | 34% (17-50) | .57 |
| Sustained donor engraftment at 42 days (95% CI)†‡ | 95% (93-97) | 100% | 89% (80-99) | .05 |
| Grade 2-4 acute GVHD (95% CI)† | 45% (34-47) | 42% (27-57) | 49% (32-65) | .20 |
| Chronic GVHD at 1 year (95% CI)† | 29% (18-40) | 40% (23-56) | 17% (5-29) | .02 |
| 180-Day TRM (95% CI)† | 26% (16-35) | 23% (11-36) | 28% (14-41) | .36 |
∗P-value for comparison between MRD and UCB. |
†Cumulative incidence. |
‡Ten patients (MRD = 5, UCB = 5) were censored for engraftment analysis because of death prior to analysis for donor chimerism. |
Figure 1
Probability of (A) PFS and (B) OS. The probability of PFS and OS at 3 years between the 2 graft sources was comparable.
On univariate analysis, PFS was significantly worse in patients who had received a previous transplant (hazard ratio [HR] 2.1, 95% CI 1.0-4.1, P = .04), and was significantly better in recipients of Cy/Flu/TBI conditioning regimen (HR 0.5, 95% CI, 0.3-0.9, P = .03) and in patients with a pretransplant HCT CI score of <3 (HR 0.5, 95% CI, 0.3-0.8, P = .009). The same variables also affected OS; OS was significantly worse in patients who had received a previous transplant (HR 2.6, 95% CI, 1.3-5.2, P = .007) and was significantly better in patients transplanted using the Cy/Flu/TBI regimen (HR 0.4, 95% CI, 0.2-0.8, P = .006) or with pretransplant HCT CI score of <3 (HR 0.4, 95% CI, 0.2-0.7, P = .001). Pretransplant HCT CI score was the only independent predictor for both PFS and for OS on Cox regression analysis (Table 3). PFS at 3 years was 50% (95% CI, 29%-71%), 34% (95% CI, 17%-50%), and 16% (95% CI, 0%-33%) for HCT CI scores of 0, 1-2, and ≥3, respectively (P = .03). OS at 3-years for the 3 risk groups was 56% (95% CI, 33%-78%), 46% (95% CI, 29%-64%) and 23% (95% CI, 5%-40%), respectively (P = .01).
Table 3. Adjusted Cox-Regression Analysis for Factors Predicting Progression-Free and Overall Survival
| Progression-Free Survival | Overall Survival | |||
|---|---|---|---|---|
| Variable | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Donor type | ||||
| MRD | 1.0 | 1.0 | ||
| UCB | 1.31 (0.73-2.32) | .36 | 1.78 (0.93-3.42) | .08 |
| HCT CI score | ||||
| ≥3 | 1.0 | 1.0 | ||
| <3 | 0.54 (0.30-0.96) | .04 | 0.45 (0.24-0.85) | .01 |
Engraftment, GVHD, and TRM
The cumulative incidence of TRM and grade II-IV aGVHD was also similar, whereas the incidence of sustained donor engraftment and cGVHD was lower in the UCB group (Table 2 and Figure 2).
Figure 2
Cumulative incidence of (A) sustained donor engraftment, (B) acute grade II-IV GVHD, and (C) cGVHD. The cumulative incidence of aGVHD was comparable between the 2 graft sources, whereas that for donor engraftment and cGVHD was lower in UCB recipients.
TRM was higher among patients with HCT CI score of ≥3. The cumulative incidence of TRM at 180 days was 14% (95% CI, 0%-28%), 19% (95% CI, 5%-32%) and 44% (95% CI, 26%-62%) for patients with HCT CI scores of 0, 1-2, and ≥3, respectively (P < .01). On Cox regression analysis, the HCT CI score was the only independent predictor of TRM; compared to patients with a higher score, those with a score of <3 had an HR for TRM of 0.3 (95% CI, 0.1-0.7, P = .006).
Twenty-six MRD and 27 UCB HCT recipients have died. The primary causes of death were disease progression (MRD = 14, UCB = 12), infections (MRD = 6, UCB = 8), aGVHD (MRD = 5, UCB = 1), and multiorgan failure (MRD = 1, UCB = 3). Two patients from the UCB cohort died of primary graft failure; the cause of death could not be determined for 1 UCB recipient. Four patients (MRD = 1, UCB = 3) have developed second malignancies following transplantation with a resultant 2-year cumulative incidence of 13% (95% CI, 0%-26%). These include 2 patients with nonmelanoma skin cancer, 1 patient with malignant melanoma in situ, and 1 patient who developed Epstein-Barr virus related posttransplantation lymphoproliferative disorder 5 months after UCB transplant.
Discussion
We report comparable TRM and survival following allogeneic HCT after RIC using either MRD or mismatched UCB in patients between 55 and 70 years of age. Our results are also comparable to other reports of RIC HCT using either a MRD or matched volunteer adult unrelated donor in older patients 2, 3, 20, 21, 22. The limitation of advanced age for patients who could potentially benefit by allogeneic HCT has been significantly overcome by the introduction of RIC regimens 2, 20, 21, 22, 23. However, the lack of suitable donors remains a major deterrent to transplantation in older patients. Compared to their younger counterparts, the already limited probability of finding an MRD is even more restricted as their siblings may not be healthy enough to undergo graft collections or may poorly mobilize hematopoietic cells. The use of UCB, however, expands the donor pool and offers the possibility of allogeneic HCT in older patients who otherwise lack a suitable related or unrelated donor.
Cell dose is among the most critical determinants of engraftment and transplant outcome following UCB transplantation and the limited availability of hematopoietic stem cells from a single UCB unit has been the main barrier to widespread use of UCB as a donor source, especially in adults 24, 25. We have been investigating the utilization of 2 UCB units as a strategy to increase the total cell dose and have previously reported on the safety and efficacy of double unit UCB transplantation in both myeloablative and RIC settings 7, 8, 26. In this study, the majority (88%) of UCB recipients received 2 UCB units with acceptable rates of engraftment and transplant related deaths, supporting the use of this approach in older patients.
Despite the use of grafts with greater HLA disparity, UCB recipients in our study had a similar incidence of aGVHD and a significantly lower incidence of cGVHD. Other studies have suggested that UCB might be associated with a lower risk of cGVHD 8, 27, 28, 29, 30, 31, 32. However, a significantly larger proportion of patients undergoing UCB HCT in our study also received ATG as a part of their conditioning regimen and ATG has been reported to decrease the risk of cGVHD after allogeneic HCT with both myeloablative and RIC regimens 33, 34, 35.
We found the HCT CI to be a useful tool for pretransplant risk assessment in this cohort of older patients. In comparison to the original cohort (median age 45 years) used by Sorror et al [10] to describe this index, our relatively older cohort (median age 58 years) had a higher proportion of patients with 3 or more comorbidites (37% versus 28%). Although HCT CI score of ≥3 (high-risk group) was independently predictive of PFS, TRM, and OS, no significant difference was observed between the outcomes of low-risk (score 0) and intermediate-risk (score 1 and 2) groups. Although age remains an important factor determining eligibility for transplantation, the incorporation of risk assessment models such as the HCT CI into decision algorithms will further assist in selecting suitable older candidates for RIC HCT.
In conclusion, our study supports the use of HLA mismatched UCB as an alternative graft source for older patients who need a transplant but do not have an MRD. Together, use of RIC and UCB markedly extends the availability of transplant therapy to older patients previously excluded on the basis of age and lack of a suitable MRD. Healthy older HCT recipients have a low and acceptable risk of TRM, and a careful review of existing comorbidities is necessary when considering older patients for HCT.
Acknowledgments
This study was supported in part by grants from the National Cancer Institute (P01CA65493) (to J.E.W, J.S.M, and P.B.M) and Children's Cancer Research Fund (C.G.B. and J.E.W.).
References
- Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol. 2005;23:1993–2003
- HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102:2021–2030
- Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. Biol Blood Marrow Transplant. 2007;13:844–852
- . Probability of finding HLA-mismatched related or unrelated marrow or cord blood donors. Hum Immunol. 2000;61:834–840
- . The National Marrow Donor Program: improving access to hematopoietic stem cell transplantation. Clin Transpl. 1999;121–127
- Unrelated donor bone marrow transplantation: influence of HLA A and B incompatibility on outcome. Blood. 1995;86:1636–1642
- . Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood. 2003;102:1915–1919
- Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplant outcomes in 110 adults with hematological disease. Blood. 2007;110:3064–3070
- . Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood. 2006;107:3804–3807
- Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–2919
- . Double umbilical cord blood transplantation. Curr Opin Immunol. 2006;18:571–575
- Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA. 1995;92:10119–10122
- . Comparison of short tandem repeat and variable number tandem repeat genetic markers for quantitative determination of allogeneic bone marrow transplant engraftment. Bone Marrow Transplant. 2002;29:243–248
- . Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. Blood. 1995;85:1954–1963
- Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250–259
- 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–828
- . Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med. 1997;16:901–910
- . Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
- . Regression models and life tables. J R Stat Soc B. 1972;34:187–220
- Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390–3400
- Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukemia. 2005;19:7–12
- A non-myeloablative conditioning regimen in allogeneic stem cell transplantation from related and unrelated donors in elderly patients. Haematologica. 2006;91:852–855
- Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant. 2006;37:339–344
- Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100:1611–1618
- . Adult umbilical cord blood transplantation: a comprehensive review. Bone Marrow Transplant. 2006;38:83–93
- Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005;105:1343–1347
- Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood. 2001;97:2962–2971
- . Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood. 2001;97:2957–2961
- Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med. 2000;342:1846–1854
- Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351:2276–2285
- . Comparable results of umbilical cord blood and HLA matched sibling donor hematopoietic stem cell transplant after reduced-intensity preparative regimen for advanced Hodgkin's lymphoma. Blood. 2006;107:3804–3807
- Chronic graft versus host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB). ASH Annu Meet Abstr. 2005;106:1814
- In vivo T cell depletion with low-dose rabbit antithymocyte globulin results in low transplant-related mortality and low relapse incidence following unrelated hematopoietic stem cell transplantation. J Hematother Stem Cell Res. 2002;11:731–737
- Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution. Transplantation. 2003;75:2135–2143
- Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006;12:560–565
PII: S1083-8791(07)00655-6
doi:10.1016/j.bbmt.2007.12.488
© 2008 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Volume 14, Issue 3 , Pages 282-289, March 2008
